[Not Yet Scheduled]
use of a contact lens/clear corneal bandage, increasing the efficacy of the medication. The company’s new and distinctive solution offers continuous dosing of drugs to the eye using a well-established, safe and accepted platform -contact lenses/corneal bandage- that replaces topical eye drops, initially for pre and post Cataract Surgery/LASIK (corneal modeling surgery) and Corneal Abrasions. The technology offers three distinct commercial opportunities to the eye care market: 1) Replacement of eye drops by continuous dosing administered by an eye care professional relieving the patient from administering their own medication; 2) Providing a new route of administration for existing eye drop pharmaceutical companies with the possibility of a better Therapeutic Index and new intellectual property; 3) delivering comfort agents to existing daily and extended-wear lens companies to reduce lens “Drop Out Rates “ by making the lenses more comfortable throughout the wear time.
Investment Highl
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
New Jersey
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
drug eluting contact lens / corneal bandage
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
President & CEO
OcuMedic, Inc.